## Edgar Filing: TherapeuticsMD, Inc. - Form 4

Therapeutie Form 4	csMD, Inc.										
June 17, 20									OMB	APPROVAL	
FORM 4 UNITED STATES SECURITIES AND EXCHA Washington, D.C. 20549										3235-0287 January 31,	
if no longer subject to Section 16. Form 4 or Form 5 Filed pursuant to				SECU	RITIES	Expires: 200 Estimated average burden hours per response 0					
obligat may co <i>See</i> Ins 1(b).	ions Section 17	(a) of the l	Public I	Utility Ho		bany A	Act of	1935 or Section	on		
(Print or Type	e Responses)										
1. Name and Address of Reporting Person <sup>*</sup> Collins Cooper C. (Last) (First) (Middle) 10003 WOODLOCH FOREST, #950 (Street)			Symbol		nd Ticker or T	-	5. Relationship of Reporting Person(s) to Issuer				
			-		D, Inc. [TXI	MDJ		(Check all applicable)			
				/Day/Year)	Transaction		XDirector10% Owner Officer (give titleOther (specify below)below)				
				nendment, l ionth/Day/Ye	Date Original ear)			6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person			
THE WOO	DDLANDS, TX 7	7380						Form filed by I Person	More than One	Reporting	
(City)	(State)	(Zip)	Ta	ble I - Non	-Derivative Se	ecuriti	es Acq	uired, Disposed o	of, or Benefic	ally Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	any Code (Instr. 3, 4 and 5) (Month/Day/Year) (Instr. 8) (A) or		5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)					
Common Stock (1)	06/14/2013			Code V	Amount 2,631,579	(D) D	Price \$ 1.75		I	Permix Therapeutics Holdings, Inc.	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transac Code (Instr. 8	Securi Acqui (A) or Dispos of (D) (Instr.	per ative ities ired r osed ) . 3,			Secur	unt of rlying	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secu Bene Owna Follo Repo Trans (Instr
				Code	4, and V (A) (		Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

## Edgar Filing: TherapeuticsMD, Inc. - Form 4

# **Reporting Owners**

Reporting Owner Name / Addres	55	Relationships							
	Director	10% Owner	Officer	Other					
Collins Cooper C. 10003 WOODLOCH FORES #950 THE WOODLANDS, TX 773	Х								
Signatures									
/s/ Cooper C. 0 Collins	6/17/2013								
<u>**</u> Signature of	Date								

#### <u>\*\*</u>Signature of Reporting Person

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- The sale of the 2,631,579 shares was made by Pernix Therapeutics Holdings, Inc. ("Pernix"). Mr. Collins is an officer, director and largest (1) shareholder of Pernix and exercises voting control in part with the remaining directors of Pernix; however, he disclaims beneficial
- ownership of the shares.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.